NPI: 1912303579 · BLUE SPRINGS, MO 64014 · General Acute Care Hospital · NPI assigned 11/10/2014
Authorized official DOAN, CHRISTOPHER controls 20+ related entities in our dataset. Read more
| Authorized Official | DOAN, CHRISTOPHER (MANAGING ASSOCIATE GENERAL COUNSEL) |
| NPI Enumeration Date | 11/10/2014 |
Other providers sharing the same authorized official: DOAN, CHRISTOPHER
| Year | Claims | Total Paid |
|---|---|---|
| 2018 | 5,918 | $2.47M |
| 2019 | 6,584 | $2.36M |
| 2020 | 9,765 | $1.92M |
| 2021 | 10,142 | $266K |
| 2022 | 16,963 | $1.03M |
| 2023 | 24,060 | $1.64M |
| 2024 | 8,642 | $816K |
| Code | Description | Claims | Beneficiaries | Total Paid |
|---|---|---|---|---|
| 99283 | Emergency department visit for the evaluation and management, moderate severity | 12,210 | 11,280 | $1.86M |
| 99284 | Emergency department visit for the evaluation and management, high severity | 6,210 | 5,694 | $1.76M |
| 99285 | Emergency department visit for the evaluation and management, high severity with immediate threat to life | 4,880 | 4,233 | $1.49M |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 9,779 | 8,327 | $1.06M |
| 80053 | Comprehensive metabolic panel | 8,615 | 7,296 | $978K |
| X4014 | 2,240 | 1,759 | $748K | |
| X4011 | State-specific procedure code | 1,618 | 1,378 | $611K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 3,554 | 1,651 | $521K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 3,230 | 2,641 | $198K |
| 71045 | Radiologic examination, chest; single view | 2,525 | 2,141 | $190K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 1,624 | 1,419 | $145K |
| 81025 | 2,040 | 1,843 | $142K | |
| 83690 | 2,351 | 2,027 | $106K | |
| 36415 | Collection of venous blood by venipuncture | 4,201 | 3,036 | $95K |
| 81001 | 1,846 | 1,615 | $77K | |
| 81003 | 1,345 | 1,155 | $76K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | 352 | 327 | $72K |
| 87081 | 158 | 147 | $54K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 1,921 | 1,692 | $53K |
| 84484 | 1,592 | 1,142 | $44K | |
| 96361 | Intravenous infusion, hydration; each additional hour | 887 | 799 | $37K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 2,817 | 2,512 | $34K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 728 | 537 | $26K |
| 80305 | 340 | 283 | $22K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 159 | 142 | $17K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 1,551 | 1,373 | $17K |
| 87086 | Culture, bacterial; quantitative colony count, urine | 282 | 249 | $13K |
| 82550 | 135 | 104 | $10K | |
| 96375 | Therapeutic injection; each additional sequential IV push | 295 | 259 | $9K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 186 | 162 | $7K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 29 | 26 | $6K |
| X4003 | 30 | 26 | $6K | |
| 85730 | 44 | 36 | $3K | |
| 85610 | 48 | 40 | $3K | |
| 80048 | Basic metabolic panel (calcium, ionized) | 544 | 486 | $3K |
| 70450 | Computed tomography, head or brain; without contrast material | 56 | 51 | $2K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | 14 | 12 | $2K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 95 | 84 | $2K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 27 | 25 | $2K |
| 83735 | 140 | 114 | $471.35 | |
| 83880 | 16 | 14 | $325.76 | |
| 83605 | 58 | 42 | $306.41 | |
| 87807 | 28 | 28 | $229.95 | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 17 | 12 | $185.47 |
| 85027 | 82 | 67 | $149.47 | |
| 87077 | 16 | 13 | $115.72 | |
| 80076 | 17 | 16 | $90.47 | |
| 86140 | 23 | 17 | $34.21 | |
| J3490 | Unclassified drugs | 1,119 | 859 | $0.00 |